Jakavi 20mg Tablet
Marketer
Novartis India Ltd
Salt Composition
Ruxolitinib (20mg)
Overview Jakavi 20mg Tablet
In the management of chronic idiopathic myelofibrosis and polycythemia vera, Jakavi 20mg tablets are prescribed. This medication can be administered with or without food, but consistent daily timing maximizes therapeutic efficacy. Dosage and frequency are determined by your physician, depending on your specific condition and may be adjusted. Adhere strictly to your doctor's instructions; improper usage or overdose can lead to severe adverse effects. While benefits may not be apparent immediately (weeks or months may pass), discontinue use only as directed by your doctor. Common side effects include headache, dizziness, and thrombocytopenia (low platelet count). Jakavi may decrease blood cell counts, increasing infection risk; regular blood tests monitoring blood cell levels, alongside cardiac, hepatic, renal, and lipid profiles, are essential. Inform your doctor of any pre-existing liver or kidney conditions, or concurrent medications (especially anti-infectives), as interactions are possible. Concurrent medication use should always be disclosed to your healthcare provider due to potential interactions. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception for both partners is crucial during treatment. A patient support/assistance program, administered by Tata 1mg, exists in India; contact your physician or call 1800-102-1618 for further information.
Primary Ingredients of Jakavi 20mg Tablet
The provided text is "undefined," therefore no rephrasing is possible.
Uses of Jakavi 20mg Tablet
Essential thrombocythemia and myelofibrosis
Major Benefits of Jakavi 20mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. The Jakavi 20mg Tablet should be swallowed whole; do not alter its form in any way. While you can take it with or without food, consistent timing is recommended.
Common Side effects of Jakavi 20mg Tablet:
- Headache
- Dizziness
- Low blood platelets
- Anemia (low number of red blood cells)
How to use Jakavi 20mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 20mg Jakavi tablet whole; avoid chewing, crushing, or breaking it. While Jakavi can be administered with or without food, consistent timing is recommended.
How Jakavi 20mg Tablet works:
Ruxolitinib 20mg tablets are a cancer treatment that inhibits the activity of a faulty protein responsible for cancer cell proliferation, thus hindering or slowing tumor growth.
SAFETY ADVICE
AlcoholSAFE
Ingesting alcohol alongside Jakavi 20mg tablets presents no known adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Use of Jakavi 20mg tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against potential hazards prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Jakavi 20mg tablets while breastfeeding is likely inadvisable. Available data from humans indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Ruxolitinib 20mg tablets can cause drowsiness, blurred vision, and dizziness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Patients with kidney impairment should use Jakavi 20mg tablets cautiously, potentially requiring dosage modification. Physician consultation is recommended. Jakavi 20mg tablets are contraindicated for those with moderate to severe kidney disease.
LiverCAUTION
Ruxolitinib 20mg tablets require careful administration in individuals with hepatic impairment. Dosage modification of ruxolitinib 20mg tablets may be necessary. Physician consultation is advised.
What if you forget to take Jakavi 20mg Tablet :
NA
Facts to Know About Jakavi 20mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Pyrrolo[2,3-d]pyrimidine derivative |
| Developing Good Habits | No. |
| Treatment Category | Cancer Treatments |
| Actions | Kinase inhibitors targeting tyrosine |
3,018 People bought this recently